Abstract BCR:: ABL1-negative myeloproliferative neoplasms (MPNs) are clonal diseases
originating from a single hematopoietic stem cell that cause excessive production of mature …

The Philadelphia negative myeloproliferative neoplasms (MPN) compromise a
heterogeneous group of clonal myeloid stem cell disorders comprising polycythaemia vera …

Ruxolitinib (RUX) is extensively used in myelofibrosis (MF). Despite its early efficacy, most
patients lose response over time and, after discontinuation, have a worse overall survival …

Myelofibrosis (MF) is a myeloproliferative disorder that exhibits considerable biological and
clinical heterogeneity. At the two ends of the disease spectrum are the myelodepletive or …

The clinical phenotype of primary and post–polycythemia vera and postessential
thrombocythemia myelofibrosis (MF) is dominated by splenomegaly, symptomatology, a …

Allogeneic haematopoietic cell transplantation (allo-HCT) remains the only curative
approach in myelofibrosis (MF). Despite advances over recent decades, relapse and non …

The primary objective of treatment in myelofibrosis (MF) is prolongation of life, which is
currently accomplished only by allogeneic hematopoietic stem cell transplantation (AHSCT) …

Abstract TP53 mutations (TP53 MTs) have been associated with poor outcomes in various
hematologic malignancies, but no data exist regarding its role in patients with myelofibrosis …

Simple Summary Myelofibrosis is an aggressive bone marrow cancer whose clinical
presentation can be extremely heterogenous. Two distinct phenotypes, myeloproliferative …

Background Allogeneic hematopoietic stem-cell transplantation is the only curative
treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the …